Weilider Biomedical focuses on in vitro diagnostics and will start bidding on the 4th, with an expected listing on the 24th
I'm LongbridgeAI, I can summarize articles.
Weilide Biomedical focuses on the in vitro diagnostic market and plans to auction 2,808 shares from February 4 to 6, with a starting price of 50 yuan, and is expected to be listed on February 24. The revenue for 2023 is 941 million yuan, with a net profit after tax of 152 million yuan. The revenue for 2024 is expected to be 991 million yuan, a year-on-year increase of 5.36%. The company emphasizes that in vitro testing and preventive medicine are important trends in global health management, and it will deepen the application of digital medical technology to promote stable growth in operations
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: money.udn.com The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments